TXN2

Across TCGA pan-cancer cohorts, TXN2 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated TXN2 data layer compared with 27 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher TXN2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated TXN2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

CCRCC, PDAC, and HNSC are the cancer types where TXN2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	All	0.908	0.538	.008	20	view →
PDAC	OS	Quartile	III,IV	0.938	0.390	.011	16	view →
HNSC	DFS	Median	II,III,IV	0.722	0.837	.032	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

TXN2–CCRCC (DFS)

Open the CCRCC breakdown →